Cargando…
Use of Glycolysis‐Enhancing Drugs and Risk of Parkinson's Disease
BACKGROUND: Terazosin (TZ) and closely related α1‐adrenergic receptor antagonists (doxazosin [DZ] and alfuzosin [AZ]) enhance glycolysis and reduce neurodegeneration in animal models. Observational evidence in humans from several databases supports this finding; however, a recent study has suggested...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley & Sons, Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9669185/ https://www.ncbi.nlm.nih.gov/pubmed/36054705 http://dx.doi.org/10.1002/mds.29184 |